Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational

Screening for NEI Clinical Studies

NCT00001734
Conditions
Conjunctivitis, Iritis, Keratitis, Retinitis, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography

NCT01746537
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Anterior Uveitis, Posterior Uveitis, Panuveitis, Uveitis
Interventions
Not listed
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
New York, New York
Conditions
Behcet's Disease, Churg-Strauss Syndrome, Giant Cell Arteritis, Wegener Granulomatosis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
8 Years to 100 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cytomegalovirus Anterior Uveitis
Interventions
Valganciclovir Hydrochloride, Ganciclovir Sodium, Placebo Oral Tablet, Topical placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Francisco, California
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography

NCT02907814
Conditions
Uveitis
Interventions
Optical Coherence Tomography (OCT), Eye Exam
Device · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Newark, New Jersey
Completed Not applicable Interventional Results available

PEMF: an Adjunct Therapy for Anterior Uveitis

NCT01154010
Conditions
Anterior Uveitis, Iritis
Interventions
PEMF, PEMF Placebo
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Interventions
RAY121
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more
Conditions
Choroiditis, Iridocyclitis, Iritis, Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Muckle Wells Syndrome, Autoinflammatory, Behcet's Disease
Interventions
XOMA 052
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 3 Interventional Results available

Phase III Study in Refractory Behcet's Disease

NCT00995709
Conditions
Behcet Disease
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Arlington, Texas • Houston, Texas
Conditions
Anterior Uveitis
Interventions
Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection
Interventions
Valganciclovir, Ganciclovir (GCV), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Results available

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT02725177
Conditions
Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
Interventions
Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Terminated Phase 2 Interventional Results available

Tocilizumab for the Treatment of Behcet's Syndrome

NCT01693653
Conditions
Behcet Syndrome
Interventions
Tocilizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Non-infectious Anterior Uveitis
Interventions
TRS01 eye drops
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Palisades Park, New Jersey • San Antonio, Texas
Conditions
Axial Spondylarthritis (axSpA)
Interventions
Upadacitinib 15 MG [Rinvoq]
Drug
Lead sponsor
CARE ARTHRITIS LTD.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399
Conditions
Non-infectious Uveitis
Interventions
AIN457, AIN 457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
Recruiting No phase listed Observational Accepts healthy volunteers

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

NCT07065747
Conditions
Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Non-infectious Anterior Uveitis
Interventions
NS2, Prednisolone acetate ophthalmic suspension (1%)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Lancaster, California • Golden, Colorado • Hamden, Connecticut + 12 more